| Q37358673 | "Metroticket" predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China |
| Q99579335 | "Six-and-twelve" score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort |
| Q57153630 | "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? |
| Q41850280 | (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma. |
| Q41706815 | 18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma |
| Q28392783 | 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma |
| Q28394414 | 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma |
| Q97543775 | A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements |
| Q38566746 | A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a "Blended Principle Model". |
| Q88341477 | A Point-based Histologic Scoring System for Hepatocellular Carcinoma Can Stratify Risk of Posttransplant Tumor Recurrence |
| Q42064611 | A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma |
| Q92797759 | A global view of hepatocellular carcinoma: trends, risk, prevention and management |
| Q39457138 | A mathematical model for optimizing the indications of liver transplantation in patients with hepatocellular carcinoma |
| Q83310713 | A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list |
| Q44374916 | A non-smooth tumor margin on preoperative imaging assesses microvascular invasion of hepatocellular carcinoma: A systematic review and meta-analysis |
| Q47890330 | A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation |
| Q35546984 | A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization |
| Q38059620 | A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. |
| Q47657432 | AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma. |
| Q92531799 | AGMA Score: A Novel Prognostic Score for Patients Undergoing Liver Transplant for Hepatocellular Carcinoma |
| Q37468851 | Accomplishments in 2008 in the management of hepatobiliary cancers. |
| Q64061259 | Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study |
| Q61800461 | Achieving Complete Remission of Hepatocellular Carcinoma: A Significant Predictor for Recurrence-Free Survival after Liver Transplantation |
| Q89762212 | Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma |
| Q37614595 | Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications |
| Q39466409 | Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study |
| Q38065315 | Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this? |
| Q89416290 | Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation |
| Q35126433 | Alloimmune activation promotes anti-cancer cytotoxicity after rat liver transplantation |
| Q36082480 | Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again |
| Q92355660 | An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study |
| Q36425910 | Antitumor activity of type I and type III interferons in BNL hepatoma model |
| Q53220944 | Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. |
| Q45941592 | Appropriate surgical therapy for patients with hepatocellular carcinoma beyond Milan criteria. |
| Q91700043 | Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol |
| Q37962184 | Are patients with Child's A cirrhosis and hepatocellular carcinoma appropriate candidates for liver transplantation? |
| Q41962614 | Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update |
| Q56335977 | Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors |
| Q33751835 | Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis |
| Q47160952 | Association between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma after Liver Transplantation |
| Q57469823 | Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma |
| Q93063121 | Association of Tumor Grade With Long-Term Survival in Patients With Hepatocellular Carcinoma After Liver Transplantation |
| Q41430971 | BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. |
| Q43040549 | Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients |
| Q84388181 | Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study |
| Q47700671 | Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series. |
| Q37636484 | Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis |
| Q39301968 | Beyond the Milan criteria for liver transplantation in children with hepatic tumours. |
| Q33893756 | Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation |
| Q89953523 | Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation |
| Q38283671 | Bridging and downstaging to transplantation in hepatocellular carcinoma |
| Q26852105 | Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation |
| Q47136271 | Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation |
| Q48326665 | Bridging to liver transplantation in HCC patients |
| Q64895129 | C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. |
| Q59799835 | CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC) |
| Q36852128 | COMPARATIVE STUDY ON LIVER TRANSPLANTATION WITH AND WITHOUT HEPATOCELLULAR CARCINOMA WITH CIRRHOSIS: ANALYSIS OF MELD, WAITING TIME AND SURVIVAL. |
| Q41308909 | CT-guided Interstitial Brachytherapy of Hepatocellular Carcinoma before Liver Transplantation: an Equivalent Alternative to Transarterial Chemoembolization? |
| Q36111140 | Can living donor liver transplantation offer similar outcomes to deceased donor liver transplantation using expanded selection criteria for hepatocellular carcinoma? |
| Q89796220 | Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation |
| Q38515812 | Cellular prognostic markers in hepatocellular carcinoma |
| Q89959739 | Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma |
| Q88581876 | Changing Paradigm in the Surgical Management of Hepatocellular Carcinoma With Salvage Transplantation |
| Q41706847 | Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives |
| Q42214107 | Child-Pugh A hepatitis B-related cirrhotic patients with a single hepatocellular carcinoma up to 5 cm: liver transplantation vs. resection |
| Q58215194 | Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma |
| Q40240706 | Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation |
| Q37068256 | Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation |
| Q38406220 | Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma |
| Q64060066 | Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma |
| Q57792485 | Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation |
| Q34169336 | Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. |
| Q42620760 | Combining 18F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma |
| Q33820376 | Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma |
| Q51037602 | Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation. |
| Q91097638 | Comparison of 3 Explant-Based Prognostic Models as Predictors of Hepatocellular Carcinoma Recurrence After Liver Transplantation: Analysis of Our Experience |
| Q93102426 | Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study |
| Q53191677 | Comparison of Two Types of Liquid Biopsies in Patients With Hepatocellular Carcinoma Awaiting Orthotopic Liver Transplantation. |
| Q35473069 | Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma |
| Q30245396 | Comparison of hepatocellular carcinoma in Eastern versus Western populations. |
| Q46170972 | Complete tumor encapsulation on magnetic resonance imaging: a potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma |
| Q90385930 | Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation |
| Q38219801 | Consensus report from the 6th International forum for liver MRI using gadoxetic acid |
| Q41659507 | Contemporary strategies in the management of hepatocellular carcinoma |
| Q26740332 | Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma |
| Q47964964 | Contribution of virtual biopsy to the screening of microvascular invasion in hepatocellular carcinoma: A pilot study. |
| Q89623916 | Controversies in the management of hepatocellular carcinoma |
| Q47614432 | Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): A Surveillance, Epidemiology, End Results (SEER) analysis |
| Q37864612 | Critical review of controversial issues in the management of advanced pediatric liver tumors |
| Q48092299 | Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. |
| Q38640531 | Curative therapies for hepatocellular carcinoma: an update and perspectives |
| Q89474143 | Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update |
| Q26740375 | Current Treatment Approaches to HCC with a Special Consideration to Transplantation |
| Q34623730 | Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review |
| Q38820685 | Current challenges and future directions for liver transplantation. |
| Q37769279 | Current controversies surrounding liver transplantation for hepatocellular carcinoma |
| Q84121761 | Current management of hepatocellular cancer |
| Q87604943 | Current management of hepatocellular carcinoma |
| Q43093342 | Current management strategy of hepatocellular carcinoma |
| Q38019845 | Current opinion on the role of resection and liver transplantation for hepatocellular cancer |
| Q34135201 | Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine |
| Q42183293 | D-MELD risk capping improves post-transplant and overall mortality under markov microsimulation |
| Q58011404 | Das hepatozelluläre Karzinom |
| Q33926379 | Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib |
| Q36976141 | Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma |
| Q35985337 | Delayed-onset cytomegalovirus disease coded during hospital readmission in a multicenter, retrospective cohort of liver transplant recipients. |
| Q36278672 | Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer. |
| Q89609286 | Descriptive Analysis of Everolimus Conversion in Liver Transplant Recipients With Malignant Neoplastic Disease |
| Q46093050 | Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection |
| Q97543823 | Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy |
| Q93197169 | Development and validation of a prediction model for microvascular invasion in hepatocellular carcinoma |
| Q38762988 | Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis |
| Q38533017 | Developments in cancer vaccines for hepatocellular carcinoma |
| Q38408866 | Diagnosis and treatment of hepatocellular carcinoma: An update |
| Q44481786 | Diagnosis of and therapy for hepatocellular carcinoma |
| Q35790414 | Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization |
| Q89928773 | Downstaging for hepatocellular cancer: harm or benefit? |
| Q36733226 | Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria |
| Q35095985 | Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy |
| Q50093611 | Early stage liver cancer : Hepatocellular carcinoma |
| Q28651675 | Effect of liver regeneration on malignant hepatic tumors |
| Q36493616 | Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study |
| Q83823143 | Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection |
| Q89641606 | Enlarged selection criteria for hepatocellular cancer: is the upper limit needed? |
| Q39064309 | Epidemiology and treatment of hepatocellular carcinoma in Thailand |
| Q37097801 | Epidemiology of Bloodstream Infections in a Multicenter Retrospective Cohort of Liver Transplant Recipients |
| Q37299603 | Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease |
| Q96111332 | Essential updates 2018/2019: Liver transplantation |
| Q51767959 | Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation. |
| Q52670491 | Evaluating the Ability of the New Subclassification to Prognosticate Outcomes Following Hepatectomy for Patients with HBV-Related HCC. |
| Q39445366 | Evaluation of Recurrence Predictors and Survival Probability After Liver Transplantation for Hepatocellular Carcinoma: Analysis From a Single Center |
| Q37260604 | Evaluation of eligibility criteria in living donor liver transplantation for hepatocellular carcinoma by α-SMA-positive cancer-associated fibroblasts |
| Q99712233 | Evaluation of the Alpha-Fetoprotein Model for Predicting Recurrence and Survival in Patients With Hepatitis B Virus (HBV)-Related Cirrhosis Who Received Liver Transplantation for Hepatocellular Carcinoma |
| Q43666308 | Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer. |
| Q41604335 | Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series |
| Q90698334 | Evolution and current status of the subclassification of intermediate hepatocellular carcinoma |
| Q96111340 | Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience |
| Q38585074 | Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest |
| Q46145394 | Excellent Outcomes of Liver Transplantation Following Down Staging of Hepatocellular Carcinoma to Within Milan Criteria-a Multi-Center Study |
| Q53339651 | Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. |
| Q35809622 | Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation |
| Q53284674 | Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. |
| Q89894899 | Expanding Indications for Liver Transplant: Tumor and Patient Factors |
| Q36241124 | Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio |
| Q57167305 | Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions |
| Q42112265 | Expression and clinical significance of Nectin-4 in hepatocellular carcinoma |
| Q83627763 | Extended criteria for living donor liver transplantation in patients with advanced hepatocellular carcinoma |
| Q88155945 | Extending transplantation criteria for hepatocellular carcinoma |
| Q90704920 | Factors Affecting Recurrence and Survival After Liver Transplantation for Hepatocellular Carcinoma |
| Q36662813 | Factors predicting survival after post-transplant hepatocellular carcinoma recurrence |
| Q91968992 | Favourable outcome of pathologic downstaging by locoregional treatment for hepatocellular carcinoma in liver transplantation |
| Q40115217 | Filamin A expression predicts early recurrence of hepatocellular carcinoma after hepatectomy. |
| Q34672331 | Frequency, risk factors and survival associated with an intrasubsegmental recurrence after radiofrequency ablation for hepatocellular carcinoma. |
| Q92377286 | From a Philosophical Framework to a Valid Prognostic Staging System of the New "Comprehensive Assessment" for Transplantable Hepatocellular Carcinoma |
| Q34966860 | From minimal to maximal surgery in the treatment of hepatocarcinoma: A review |
| Q35925442 | Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and (18)F-FDG PET/CT in patients on waiting-list for liver transplantation. |
| Q37765050 | Future perspectives in hepatocellular carcinoma |
| Q36759564 | Gene-expression signature of vascular invasion in hepatocellular carcinoma. |
| Q33960740 | Good longterm survival after primary living donor liver transplantation for solitary hepatocellular carcinomas up to 8 cm in diameter. |
| Q39548324 | Growth of hepatocellular carcinoma in the regenerating liver |
| Q48247468 | Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases |
| Q38976824 | HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? |
| Q37980015 | HCC: current surgical treatment concepts |
| Q37886275 | HCV-related liver cancer in people with haemophilia. |
| Q42685478 | Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria |
| Q90449791 | Hepatic resection for primary and secondary liver malignancies |
| Q58021316 | Hepatocellular Carcinoma |
| Q58021436 | Hepatocellular Carcinoma |
| Q92477187 | Hepatocellular Carcinoma and Liver Transplantation: A Single-Center Experience |
| Q29994588 | Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices |
| Q26781798 | Hepatocellular Carcinoma and Liver Transplantation: State of the Art |
| Q26866311 | Hepatocellular Carcinoma in Liver Cirrhosis: Surgical Resection versus Transarterial Chemoembolization-A Meta-Analysis |
| Q42053469 | Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy |
| Q28071444 | Hepatocellular Carcinoma: The Role of Interventional Oncology |
| Q89379957 | Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? |
| Q29616359 | Hepatocellular carcinoma |
| Q57756376 | Hepatocellular carcinoma |
| Q58020832 | Hepatocellular carcinoma |
| Q92324393 | Hepatocellular carcinoma - time to take the ticket |
| Q42912745 | Hepatocellular carcinoma and cholangiocarcinoma |
| Q38163597 | Hepatocellular carcinoma and cholangiocarcinoma: an update |
| Q42256347 | Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria |
| Q38962965 | Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA. |
| Q43503984 | Hepatocellular carcinoma in Child's A cirrhosis: a retrospective analysis of matched pairs following liver transplantation vs. liver resection according to the intention-to-treat principle |
| Q98195434 | Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence |
| Q38604896 | Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient |
| Q64116476 | Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation |
| Q38207012 | Hepatocellular carcinoma review: current treatment, and evidence-based medicine |
| Q84958635 | Hepatocellular carcinoma--resection or transplant? |
| Q28087638 | Hepatocellular carcinoma: A comprehensive review |
| Q35626757 | Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome |
| Q26783881 | Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols |
| Q37863539 | Hepatocellular carcinoma: MR staging and therapeutic decisions. |
| Q35626761 | Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives |
| Q38217436 | Hepatocellular carcinoma: a comprehensive overview of surgical therapy |
| Q35112053 | Hepatocellular carcinoma: clinical frontiers and perspectives |
| Q58097274 | Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5–7 cm) and very large (>7 cm) tumours |
| Q37578500 | Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. |
| Q37813192 | Hepatocellular carcinoma: diagnostics and screening |
| Q33881131 | Hepatocellular carcinoma: early-stage management challenges |
| Q34409128 | Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. |
| Q38224434 | Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations |
| Q88791892 | Hepatocellular carcinoma: when is liver transplantation oncologically futile? |
| Q34508914 | High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma |
| Q38283692 | How does selective internal radiation therapy compare with and/or complement other liver-directed therapies |
| Q27001669 | How grim is hepatocellular carcinoma? |
| Q40931102 | Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma |
| Q38966325 | Human immunodeficiency virus-infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study |
| Q37076019 | Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery |
| Q35143323 | Identification of Zinc Finger, MYM-type 2 (ZMYM2) as a regulator of sorafenib resistance in hepatocellular carcinoma cell lines |
| Q89782505 | Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort |
| Q30962577 | Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: Data mining analysis |
| Q64101758 | Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation |
| Q53839990 | Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. |
| Q40603978 | Impact of Histological Factors of Hepatocellular Carcinoma on the Outcome of Liver Transplantation |
| Q89309144 | Impact of Perioperative Phosphorus and Glucose Levels on Liver Regeneration and Long-term Outcomes after Major Liver Resection |
| Q95424115 | Impact of model for end-stage liver disease score on long-term survival following liver transplantation for hepatocellular carcinoma |
| Q26766049 | Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients |
| Q44696972 | Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma |
| Q44073825 | Inappropriate inferences from registry data: Pitfalls of inaccurate data handling? |
| Q35785027 | Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. |
| Q33558068 | Incidental hepatocellular carcinoma after liver transplantation: Prevalence, histopathological features and prognostic impact |
| Q42212127 | Incidental hepatocellular carcinoma: risk factors and long-term outcome after liver transplantation. |
| Q57642011 | Incidentally discovered hepatocellular carcinoma in explanted liver: clinical, histopathologic features and outcome |
| Q37314134 | Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). |
| Q37360166 | Indications for living donor liver transplantation in patients with hepatocellular carcinoma |
| Q50998467 | Infiltrating memory/senescent T cell ratio predicts extrahepatic metastasis of hepatocellular carcinoma. |
| Q85205826 | Inhibition of mammalian target of rapamycin: Two goals with one shot? |
| Q43107477 | Inhibition of mammalian target of rapamycin: the janus face of immunosuppression? |
| Q38707454 | Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer |
| Q21296797 | Interferon lambda: a new sword in cancer immunotherapy |
| Q38110203 | Intermediate hepatocellular carcinoma: current treatments and future perspectives |
| Q91532477 | Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation? |
| Q26764997 | Is There a Role for Liver Transplantation in Non-Colorectal Liver Metastases? |
| Q37795703 | Is it time to reconsider the BCLC/AASLD therapeutic flow‐chart? |
| Q37728257 | Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? A comparison of eight guidelines. |
| Q38237510 | Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation |
| Q64263964 | It is time to abandon the Milan criteria |
| Q38838078 | Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6. |
| Q37183805 | LIN28 expression and prognostic value in hepatocellular carcinoma patients who meet the Milan criteria and undergo hepatectomy |
| Q37579484 | LIVER TRANSPLANTATION FOR CARCINOMA HEPATOCELLULAR IN SÃO PAULO: 414 CASES BY THE MILAN/BRAZIL CRITERIA. |
| Q38795386 | Laparoscopic Resection of Recurrence from Hepatocellular Carcinoma after Liver Transplantation: Case Reports and Review of the Literature. |
| Q34108430 | Laser ablation for small hepatocellular carcinoma. |
| Q39037188 | Limitations of predicting microvascular invasion in patients with hepatocellular cancer prior to liver transplantation |
| Q90749863 | Liver Grafts with Major Extended Donor Criteria May Expand the Organ Pool for Patients with Hepatocellular Carcinoma |
| Q30276330 | Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria |
| Q91795139 | Liver Transplantation Beyond Milan Criteria |
| Q89987746 | Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria |
| Q50099732 | Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. |
| Q38078347 | Liver Transplantation for HCC: A Review |
| Q57066918 | Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong |
| Q63367353 | Liver Transplantation for Hepatocellular Carcinoma |
| Q36962089 | Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome |
| Q89057724 | Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma |
| Q90700395 | Liver Transplantation for Progressive Unresectable Colorectal Liver Metastases: Case Report and Review of the Literature |
| Q54773237 | Liver Transplantation for a Patient with Hepatocellular Carcinoma with Vascular Invasion and Exceeding Milan Criteria-Happy End Despite it all. |
| Q38979742 | Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma |
| Q35903794 | Liver cancer: Approaching a personalized care |
| Q37702183 | Liver regeneration microenvironment of hepatocellular carcinoma for prevention and therapy |
| Q47155638 | Liver resection versus transplantation for multiple hepatocellular carcinoma: a propensity score analysis |
| Q90070899 | Liver transplant for patients outside Milan criteria |
| Q38046482 | Liver transplantation and expanded Milan criteria: does it really work? |
| Q55226872 | Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours. |
| Q38519906 | Liver transplantation as a management of hepatocellular carcinoma |
| Q47325009 | Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma |
| Q37626584 | Liver transplantation for HCC: its role: Eastern and Western perspectives |
| Q30452202 | Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions |
| Q28074653 | Liver transplantation for advanced hepatocellular carcinoma |
| Q27021650 | Liver transplantation for hepatic tumors: a systematic review |
| Q38121508 | Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues |
| Q38821374 | Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun |
| Q45284698 | Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria. |
| Q91656445 | Liver transplantation for hepatocellular carcinoma |
| Q84950960 | Liver transplantation for hepatocellular carcinoma |
| Q38635611 | Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival |
| Q24658550 | Liver transplantation for hepatocellular carcinoma beyond the Milan criteria |
| Q26750463 | Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review |
| Q87010059 | Liver transplantation for hepatocellular carcinoma exceeding the Milan criteria: a single-center experience |
| Q37035208 | Liver transplantation for hepatocellular carcinoma in Ireland: Pre-operative alpha-fetoprotein predicts tumour recurrence in a 14-year single-centre national experience |
| Q43000512 | Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence |
| Q34045701 | Liver transplantation for hepatocellular carcinoma--is there a risk of recurrence caused by intraoperative blood salvage autotransfusion? |
| Q64980905 | Liver transplantation for hepatocellular carcinoma: Where do we stand? |
| Q37140667 | Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies |
| Q39739700 | Liver transplantation for hepatocellular carcinoma: an update. |
| Q43916781 | Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America |
| Q46731850 | Liver transplantation for hepatocellular carcinoma: how far can the selection criteria be expanded? |
| Q39067623 | Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches |
| Q35779474 | Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence |
| Q38211859 | Liver transplantation for hepatocellular carcinoma: past, present and future |
| Q38177251 | Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis |
| Q42349921 | Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. |
| Q38194071 | Liver transplantation for malignancies |
| Q33594868 | Liver transplantation for malignancy: current treatment strategies and future perspectives |
| Q37360177 | Liver transplantation for small hepatocellular carcinoma |
| Q36220176 | Liver transplantation in adults: Choosing the appropriate timing |
| Q96946017 | Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial |
| Q43787353 | Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience |
| Q38878205 | Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma |
| Q83101016 | Liver-cell cancer and transplantation |
| Q33872038 | Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? |
| Q34067940 | Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation |
| Q88979476 | Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure? |
| Q28073611 | Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes |
| Q37972811 | Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience |
| Q38221511 | Living donor liver transplantation for patients with hepatocellular carcinoma |
| Q44942457 | Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. |
| Q38757577 | Living donor liver transplantation: eliminating the wait for death in end-stage liver disease? |
| Q89953527 | Living vs. deceased-donor liver transplantation for patients with hepatocellular carcinoma |
| Q37708048 | Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison |
| Q37766546 | Loco-regional treatment of hepatocellular carcinoma |
| Q60922515 | Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation |
| Q64054771 | Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria |
| Q91973944 | Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre |
| Q35422169 | Long-term outcomes of hepatic resection versus living donor liver transplantation for hepatocellular carcinoma: a propensity score-matching study |
| Q90642620 | Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging |
| Q92915718 | Long-term quality of life after liver transplantation for non-resectable colorectal metastases confined to the liver |
| Q52699069 | Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. |
| Q37247967 | Magnitude of change in alpha-fetoprotein in response to transarterial chemoembolization predicts survival in patients undergoing liver transplantation for hepatocellular carcinoma. |
| Q46115260 | Major achievements in hepatocellular carcinoma |
| Q28258769 | Management of HCC |
| Q37625446 | Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. |
| Q36955647 | Management of hepatocellular carcinoma: Enlightening the gray zones. |
| Q38811107 | Management of patients with colorectal liver metastasis in eleven questions and answers |
| Q90667742 | Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation |
| Q96225027 | Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective |
| Q35818336 | Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review |
| Q38344890 | Managing complications in cirrhotic patients |
| Q37895618 | Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? |
| Q52630599 | Matrix Metalloproteinase 1 as a Novel Biomarker for Monitoring Hepatocellular Carcinoma in Liver Transplant Patients. |
| Q38059437 | Medical therapies for hepatocellular carcinoma: a critical view of the evidence |
| Q42588893 | Medical treatment of hepatocellular carcinoma |
| Q38070693 | Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma |
| Q41697309 | Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay |
| Q36251812 | Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B. |
| Q36682732 | Microvascular invasion in hepatocellular carcinoma |
| Q53512138 | Microwave ablation for the treatment of hepatocellular carcinoma that met up-to-seven criteria: feasibility, local efficacy and long-term outcomes. |
| Q42322512 | Milan Criteria and UCSF Criteria: A Preliminary Comparative Study of Liver Transplantation Outcomes in the United States |
| Q42333014 | Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma |
| Q97415571 | Milan criteria in the MELD era-is it justifiable to extend the limits for orthotopic liver transplantation? |
| Q83427373 | Milan criteria, up-to-seven criteria, and the illusion of a rescue package for patients with liver cancer |
| Q42610253 | Molecular classification and clonal differentiation of hepatocellular carcinoma: the step forward for patient selection for liver transplantation. |
| Q41426492 | Molecular markers predicting outcome in hepatocellular carcinoma treated by liver transplantation |
| Q38212573 | Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future |
| Q53245649 | Morphology does not tell us the entire story: biological behavior improves our ability to select patients with hepatocellular carcinoma waiting for liver transplantation. |
| Q38137238 | Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity |
| Q41963215 | Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation |
| Q26998606 | Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience |
| Q26825172 | Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update |
| Q47100371 | Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation |
| Q92174586 | National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time |
| Q33594862 | Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand? |
| Q26749329 | New advances in hepatocellular carcinoma |
| Q38035612 | New concepts and best practices for management of pre- and post-transplantation cancer. |
| Q27026454 | New insights in hepatocellular carcinoma: from bench to bedside |
| Q48328889 | New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. |
| Q48507271 | Nomogram predicting pulmonary metastasis of hepatocellular carcinoma after liver transplantation. |
| Q38371690 | Noninvasive radiomics signature based on quantitative analysis of computed tomography images as a surrogate for microvascular invasion in hepatocellular carcinoma: a pilot study. |
| Q37542835 | Novel implications in the treatment of hepatocellular carcinoma |
| Q41257562 | Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model |
| Q39289392 | Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma |
| Q46046878 | Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma. |
| Q58754758 | Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial Chemoembolization and Poor Prognosis |
| Q46303391 | OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation |
| Q38811992 | Oncogenic role of microRNA-423-5p in hepatocellular carcinoma. |
| Q51375959 | One-stage emergency right hemihepatectomy due to spontaneous rupture of hepatocellular carcinoma--case report. |
| Q34663403 | Operative therapy of hepatocellular carcinoma |
| Q34429511 | Optimal tailored screening protocol after living donor liver transplantation for hepatocellular carcinoma |
| Q41316719 | Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma |
| Q51747220 | Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma |
| Q92954733 | Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma |
| Q57788670 | Outcomes following liver resection for multinodular Barcelona Clinic Liver Cancer-B hepatocellular carcinoma |
| Q40633421 | Outcomes of Patients With Poorly Differentiated Hepatocellular Carcinoma After Liver Transplantation. |
| Q34165090 | Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation |
| Q90135434 | PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age |
| Q34986197 | Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma |
| Q90288434 | Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification |
| Q55002116 | Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: A systematic review and meta-analysis. |
| Q90749815 | Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics |
| Q37596678 | Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma |
| Q39898473 | Predicting Individual Survival After Hepatectomy for Hepatocellular Carcinoma: a Novel Nomogram from the "HCC East & West Study Group". |
| Q34548943 | Predicting recurrence patterns after resection of hepatocellular cancer |
| Q95424122 | Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma |
| Q98159016 | Predicting tumor recurrence using metabolic indices of 18F-FDG PET/CT prior to orthotopic liver transplantationfor hepatocellular carcinoma |
| Q92709313 | Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study |
| Q51731254 | Prediction of Microvascular Invasion in Hepatocellular Carcinoma: Preoperative Gd-EOB-DTPA-Dynamic Enhanced MRI and Histopathological Correlation. |
| Q92418066 | Prediction of Microvascular Tumor Invasion in Liver Transplant Candidates With Hepatocellular Carcinoma: A Feasible Concept or a Misleading Illusion? |
| Q26772329 | Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation |
| Q48233798 | Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explant-based prognostic models. |
| Q53049436 | Prediction of microvascular invasion of hepatocellular carcinoma using gadoxetic acid-enhanced MR and (18)F-FDG PET/CT. |
| Q89615027 | Predictive Models of Hepatocellular Carcinoma Recurrence After Liver Transplantation |
| Q48217612 | Predictive models for recurrence risk of hepatocellular carcinoma after liver transplantation: Still an unmet need. |
| Q98159777 | Predictor of outcome after living donor liver transplantation for patients with hepatocellular carcinoma beyond the Japan criteria |
| Q54335179 | Preliminary report of major surgery in liver transplant recipients receiving m-TOR inhibitors without therapeutic discontinuation. |
| Q99731692 | Preoperative prediction of microvascular invasion in non-metastatic hepatocellular carcinoma based on nomogram analysis |
| Q37568646 | Preoperative prognostic values of α-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation |
| Q97543793 | Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis |
| Q34461341 | Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis |
| Q47873167 | Pro (With Caution): Extended oncologic indications in liver transplantation. |
| Q42789592 | Prognosis in the early stages of hepatocellular carcinoma: Predicting outcomes and properly selecting patients for curative options |
| Q44525314 | Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B). |
| Q38216004 | Prognostic factors for hepatocellular carcinoma recurrence |
| Q42427543 | Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma |
| Q37376461 | Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a single-center study |
| Q40212610 | Prognostic prediction of male recipients selected for liver transplantation: With special attention to neutrophil to lymphocyte ratio |
| Q37235913 | Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis |
| Q35169393 | Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma |
| Q38864396 | Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment |
| Q83879767 | Progression of hepatocellular carcinoma before liver transplantation: dropout or liver transplantation? |
| Q28073769 | Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma |
| Q58789048 | Proposal for subclassification to select patients for hepatectomy with intermediate hepatocellular carcinoma and Child-Pugh A liver function: A double-center study from China |
| Q57219629 | Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer C |
| Q37350320 | Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients. |
| Q41124464 | Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. |
| Q35099250 | Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm |
| Q64993911 | Radiomics and radiogenomics of primary liver cancers. |
| Q37012028 | Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience |
| Q89624059 | Recent advances in liver transplantation for cancer: The future of transplant oncology |
| Q26863748 | Recent advances in multidisciplinary management of hepatocellular carcinoma |
| Q39095917 | Recent advances in understanding and managing liver transplantation |
| Q40756956 | Recipient C6 rs9200 genotype is associated with hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population |
| Q36902284 | Recipient ineligibility after liver transplantation assessment: a single centre experience |
| Q38030887 | Recipient outcomes of salvage liver transplantation versus primary liver transplantation: a systematic review and meta-analysis |
| Q92796957 | Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Experience |
| Q50899345 | Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection? |
| Q38594469 | Recurrence of hepatocellular carcinoma after liver transplantation: an update |
| Q83675820 | Recurrence of hepatocellular carcinoma after living donor liver transplantation: what is the current optimal approach to prevent recurrence? |
| Q40434294 | Recurrent Hepatocellular Carcinoma After Liver Transplantation: Analysis of Risk Factors. |
| Q38594974 | Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient |
| Q38045000 | Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge |
| Q51730283 | Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with HALTHCC improves ablate and wait strategy. |
| Q89609262 | Regorafenib Combined With Sirolimus Achieves Successful Treatment of Diffuse Double Lung Metastasis After Liver Transplantation in Giant Liver Cancer Beyond Transplantation Criteria: A Case Report |
| Q53473420 | Resection of right ventricular metastasis subsequent to liver transplant for hepatocellular carcinoma. |
| Q42345142 | Resection versus transplantation for hepatocellular carcinoma exceeding Milan criteria within increasing donor shortage |
| Q42237712 | Results of salvage liver transplantation. |
| Q34038193 | Retracted: A Scoring Model Based on Neutrophil to Lymphocyte Ratio Predicts Recurrence of HBV-Associated Hepatocellular Carcinoma after Liver Transplantation |
| Q31037974 | Retracted: Genetic Variations in Plasma Circulating DNA of HBV-Related Hepatocellular Carcinoma Patients Predict Recurrence after Liver Transplantation |
| Q37521126 | Retracted: Salvage Liver Transplantation for Recurrent Hepatocellular Carcinoma after Liver Resection: Retrospective Study of the Milan and Hangzhou Criteria |
| Q34510569 | Retracted: The Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection and Cirrhosis |
| Q53093022 | Retrohepatic vena cava deroofing in living donor liver transplantation for caudate hepatocellular carcinoma. |
| Q39261082 | Review article: delivering precision oncology in intermediate-stage liver cancer |
| Q38243059 | Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria |
| Q34303040 | Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation. |
| Q98289950 | Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology |
| Q44490029 | Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis |
| Q48189816 | Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model |
| Q47400891 | Risks factors for severe pain after selective liver transarterial chemoembolization |
| Q89029603 | Role of Adult Living Donor Liver Transplantation in the Treatment of Hepatocellular Carcinoma Within and Beyond Milan Criteria: A Comparative Study |
| Q64091719 | Role of Allelic Imbalance in Predicting Hepatocellular Carcinoma (HCC) Recurrence Risk After Liver Transplant |
| Q40788363 | Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers. |
| Q52885569 | Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma. |
| Q90798614 | Role of fine-needle aspiration in post liver transplant patients: A clinical/cytological review |
| Q26822581 | Role of liver transplantation for hepatocellular carcinoma |
| Q37928952 | Role of organ transplantation in the treatment of malignancies: hepatocellular carcinoma as the most common tumour treated with transplantation. |
| Q58566698 | Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation |
| Q37989160 | Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma |
| Q39824572 | SNF5 is Involved in Suppression of Hepatocellular Carcinoma Progression via TGF-Beta 1 Signaling |
| Q38907706 | Salvage Liver Transplantation Leads to Poorer Outcome in Hepatocellular Carcinoma Compared with Primary Liver Transplantation |
| Q39264320 | Samaritan donor interchange in living donor liver transplantation. |
| Q34977062 | Scoring selection criteria including total tumour volume and pretransplant percentage of lymphocytes to predict recurrence of hepatocellular carcinoma after liver transplantation |
| Q47853149 | Second primary cancer after liver transplantation in hepatocellular carcinoma: a nationwide population-based study |
| Q64882442 | Segmental Distribution of Hepatocellular Carcinoma Correlates with Microvascular Invasion in Liver Explants Undergoing Transplantation. |
| Q26744102 | Selection Criteria and Current Issues in Liver Transplantation for Hepatocellular Carcinoma |
| Q27014758 | Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation |
| Q26771246 | Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future |
| Q35895358 | Selection tool alpha-fetoprotein for patients waiting for liver transplantation: How to easily manage a fractal algorithm. |
| Q39444001 | Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma |
| Q61443474 | Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation |
| Q34660116 | Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation |
| Q37883997 | Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation? |
| Q60912071 | Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy? |
| Q37874568 | Should we perform deceased donor liver transplantation after living donor liver transplantation has failed? |
| Q83932242 | Significance of platelet count in the outcomes of hepatectomized patients with hepatocellular carcinoma exceeding the Milan criteria |
| Q39223475 | Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study |
| Q36381360 | Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. |
| Q90348096 | Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria |
| Q43148419 | Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. |
| Q38210270 | Sorafenib use in the transplant setting |
| Q37348887 | Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. |
| Q40477968 | Staging and therapy for patients with hepatocellular cancer in a defined population from 2000 to 2011 - active palliative treatment improved overall survival. |
| Q38408876 | Staging systems for hepatocellular carcinoma: Current status and future perspectives |
| Q90296549 | Stereotactic Radiofrequency Ablation of Hepatocellular Carcinoma: a Histopathological Study in Explanted Livers |
| Q37603126 | Stereotactic body radiation therapy as a bridge to transplantation and for recurrent disease in the transplanted liver of a patient with hepatocellular carcinoma |
| Q57987901 | Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization |
| Q38933888 | Strategic overview on the best treatment option for intrahepaitc hepatocellular carcinoma recurrence |
| Q27005375 | Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation |
| Q26795530 | Strategies to increase the resectability of hepatocellular carcinoma |
| Q26784407 | Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas |
| Q51130491 | Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers. |
| Q44679162 | Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization |
| Q64079337 | Successful Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Chemoembolization followed by Radical Liver Transplantation in a Patient with Severe Liver Damage |
| Q37900264 | Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement |
| Q38474433 | Super-selection of a subgroup of hepatocellular carcinoma patients at minimal risk of recurrence for liver transplantation |
| Q49670510 | Surgery for Hepatocellular Carcinoma in Patients with Child-Pugh B Cirrhosis: Hepatic Resection Versus Living Donor Liver Transplantation |
| Q54989355 | Surgical Treatment of Hepatocellular Carcinoma. |
| Q26824046 | Surgical approach for hepatitis C virus-related hepatocellular carcinoma |
| Q38769255 | Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration |
| Q55018940 | Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. |
| Q43954981 | Surgical treatment for early hepatocellular carcinoma: comparison of resection and liver transplantation |
| Q51590775 | Surgical treatment for hepatocellular carcinoma. |
| Q36192647 | Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. |
| Q42177882 | Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion |
| Q43590800 | Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. |
| Q85107768 | Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma |
| Q55293155 | Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. |
| Q55505579 | Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. |
| Q37995306 | Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma |
| Q39529070 | TNF-dependent signaling pathways in liver cancer: promising targets for therapeutic strategies?. |
| Q36928888 | Targeted therapies for hepatocellular carcinoma. |
| Q37454420 | Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis |
| Q37560333 | The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer. |
| Q39766876 | The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study |
| Q34868567 | The impact of liver transplantation after surgical treatment of hepatocellular carcinoma |
| Q44623252 | The long-term outcomes of patients with hepatocellular carcinoma after living donor liver transplantation: a comparison of right and left lobe grafts |
| Q37625811 | The management of patients awaiting liver transplantation |
| Q48194435 | The prognostic value of 18F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases |
| Q51009835 | The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. |
| Q41355820 | The reprogramming therapy for a patient with advanced hepatocellular carcinoma by using human-induced pluripotent stem (iPS) cells technology |
| Q35203669 | The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma |
| Q47162797 | The utility of biomarkers in hepatocellular carcinoma: review of urine-based 1H-NMR studies - what the clinician needs to know. |
| Q43897398 | Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma |
| Q50244078 | Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis |
| Q46326246 | Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria |
| Q35187751 | Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma |
| Q37876380 | Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation |
| Q41208111 | Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation |
| Q37920857 | Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. |
| Q56603210 | Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review |
| Q26861543 | Transplant benefit for patients with hepatocellular carcinoma |
| Q58550746 | Transplantation for colorectal metastases: on the edge of a revolution |
| Q58554770 | Transplantation for hepatocellular cancer: pushing to the limits? |
| Q92972903 | Transplantation versus liver resection in patients with hepatocellular carcinoma |
| Q38568533 | Treating ischaemia-reperfusion injury with prostaglandin E1 reduces the risk of early hepatocellular carcinoma recurrence following liver transplantation |
| Q64062234 | Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach |
| Q51454531 | Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea. |
| Q39860927 | Treatment of early hepatocellular carcinoma: How to predict and prevent recurrence |
| Q58021482 | Treatment of early hepatocellular carcinoma: Towards personalized therapy |
| Q38155508 | Treatment of hepatocellular carcinoma: a systematic review |
| Q38295870 | Treatment of hepatocellular carcinoma: beyond international guidelines. |
| Q38685608 | Treatment of hepatocellular carcinoma: beyond international guidelines. |
| Q38096477 | Treatment of hepatocellular carcinoma: present and future |
| Q37863929 | Treatment options in hepatocellular carcinoma today. |
| Q64262622 | Treatment strategies for locally advanced hepatocellular carcinoma |
| Q58021359 | Tumors of the Liver |
| Q88791889 | Twenty years after: from Milan criteria to a "blended" approach |
| Q42333007 | Twenty years of Milan criteria: how far do we go. |
| Q41901746 | Twenty years of Milan criteria: the wicked flee though no one pursues. |
| Q58415981 | Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities |
| Q39445681 | Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation |
| Q39033557 | Up-to-7 Criteria for Hepatocellular Carcinoma Liver Transplantation: A Retrospective Analysis of Experiences |
| Q37203571 | Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis |
| Q34571160 | Updates in the management of hepatocellular carcinoma |
| Q38809496 | Use of everolimus in liver transplantation: The French experience |
| Q48203129 | Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group |
| Q90087575 | Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy |
| Q41578261 | Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. |
| Q64116139 | Validated model for prediction of recurrent hepatocellular carcinoma after liver transplantation in Asian population |
| Q42695215 | Validated preoperative computed tomography risk estimation for postoperative hepatocellular carcinoma recurrence |
| Q39149264 | Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma |
| Q38795885 | Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant |
| Q35764913 | Validation of a criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation |
| Q40789036 | Validation of the "Metroticket" model in a cohort of patients transplanted for hepatocellular carcinoma in southern Brazil. |
| Q40335863 | Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. |
| Q38604477 | Validity of eleven prognostic scores with respect to intra- and extrahepatic recurrence of hepatocellular carcinoma after liver transplantation |
| Q33661046 | Value of radiofrequency ablation in the treatment of hepatocellular carcinoma |
| Q36284669 | Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes |
| Q50098792 | Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant |
| Q46456307 | Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". |
| Q30829251 | Waiting time and explant pathology in transplant recipients with hepatocellular carcinoma: a novel study using national data |
| Q37886890 | What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation? |
| Q37895616 | What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma? |
| Q41114489 | When Should We Propose Liver Transplant After Resection of Hepatocellular Carcinoma? A Comparison of Salvage and De Principe Strategies |
| Q37876384 | Which matters most: number of tumors, size of the largest tumor, or total tumor volume? |
| Q37068157 | Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives |
| Q85511192 | Yttrium 90 radioembolization: the horizon is changing for patients with intermediate and advanced hepatocellular carcinoma |
| Q40586816 | Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation |
| Q57763422 | Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study |
| Q58562671 | [Frontiers in liver transplantation in indication and techniques] |
| Q44670060 | miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver |